The DOI matches its Crossref record.
Interferon-beta: Mechanism of action and dosing issues
Abstract
In patients with multiple sclerosis (MS), activation of immune cells and breakdown of the blood-brain barrier (BBB) lead to demyelination and axon injury. Although repairing damage to neurons is not possible, immunomodulating therapies can reduce the inflammatory processes that lead to demyelination. Interferon-beta (IFN-beta) is a polypeptide, normally produced by fibroblasts, that has antiviral and antiproliferative effects. Binding of IFN-beta to its receptor induces a complex transcriptional response. In immune cells (the most likely target of IFN-beta's therapeutic effect in MS), IFN-beta reduces antigen presentation and T-cell proliferation, alters cytokine and matrix metalloproteinase (MMP) expression, and restores suppressor function. Therapeutic forms of IFN-beta can be produced in bacterial expression systems (IFN-beta1b) or in mammalian cells (IFN-beta1a). These forms have some differences in their amino acid sequence and posttranslational modifications, but the transcriptional response to IFN- beta1b and IFN-beta1a appears to be similar, if not indistinguishable. However, the biological response and the clinical effect do vary with changes in the dosing frequency of IFN-beta. In clinical trials, IFN-beta1a IM administered weekly elicits a transient biological response compared to IFN-beta1b administered SC every other day or IFN-beta1a (administered SC three times per week). Comparative clinical trials suggest that the differences in the biological response are clinically meaningful: more frequent IFN-beta administration produces superior clinical responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 10
- Chofflon M. Mechanisms of action for treatments in multiple sclerosis: does a heterogeneous disease demand a multi-targeted therapeutic approach? Bio Drugs 2005;19:299–308.
- 10.1016/0165-5728(93)90244-S · DOI · Paper page
- 10.1073/pnas.81.18.5662 · DOI · Paper page
- 10.1212/WNL.58.2.169 · DOI · Paper page
- Sturzebecher S, Maibauer R, Heuner A, Beckmann K, Aufdembrinke B. Pharmacodynamic comparison of single doses of IFN-beta1a and IFN-beta1b in healthy volunteers. J Interferon Cytokine Res 1999;19:1257–1264.
- 10.1212/WNL.54.11.2055 · DOI
- 10.1002/ana.410270219 · DOI
- 10.1046/j.1468-1331.1998.520187.x · doi:10.1046/j.1468-1331.1998.520187.x
- Baron S. The inferon system: a current review to 1987. Austin TX: University of Texas Press 1987.
- Rothuizen LE, Buclin T, Spertini F, et al. Influence of interferon beta-1a dose frequency on PBMC cytokine secretion and biological effect markers. J Neuroimmunol 1999;99:131–141.
Cited by
The Blood-Brain Barrier in Brain Homeostasis and Neurological Diseases
Weiss, N., Miller, F., Cazaubon, S., & Couraud, P.-O. (2009) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2008.10.022 · Cited by 731
Interferon-λ: Immune Functions at Barrier Surfaces and Beyond
Lazear, H. M., Nice, T. J., & Diamond, M. S. (2015) · Immunity · doi:10.1016/j.immuni.2015.07.001 · Cited by 480
The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice
Guo, B., Chang, E. Y., & Cheng, G. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33342 · Cited by 371
Interferon-β mechanisms of action in multiple sclerosis
Dhib-Jalbut, S., & Marks, S. (2010) · Neurology · doi:10.1212/wnl.0b013e3181c97d99 · Cited by 298
Daniels, B. P., Holman, D. W., Cruz-Orengo, L., Jujjavarapu, H., Durrant, D. M., & Klein, R. S. (2014) · mBio · doi:10.1128/mbio.01476-14 · Cited by 235
Metadata
- Authors
- Markowitz, C. E.
- Venue
- Neurology
- Published
- 2007-06-12
- Volume
- 68
- Issue
- 24_suppl_4
- Pages
- S8-11
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2091408937
- Cited by
- 163
- References
- 0
- FWCI
- 10.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Interferon-beta: Mechanism of action and dosing issues. https://app.cochat.ai/papers/10.1212/01.wnl.0000277703.74115.d2
- The paper
- Markowitz, C. E. (2007). Interferon-beta: Mechanism of action and dosing issues. Neurology. https://doi.org/10.1212/01.wnl.0000277703.74115.d2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.